NPC shares new IRA-related research in AJMC
WASHINGTON – The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (DPNP) may lead to fewer subsequent indications and delay launches for small molecule drugs, according to new research from the National Pharmaceutical Council (NPC) published in the American Journal of Managed